Spark’s approach to the problem of redosing AAV gene therapies

Spark aims to solve one of the big problems plaguing gene therapy -- immune responses against viral vectors -- by adapting a strategy Hansa has been developing for transplant rejection.

Past infections with adenoviruses or adeno-associated viruses can lead to pre-existing antibodies against viral vectors that both pose a safety risk

Read the full 501 word article

How to gain access

Continue reading with a
two-week free trial.